Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Conditions: Head Neck; Squamous Cell Carcinoma of Head and Neck Interventions: Drug: Pembrolizumab; Drug: Magrolimab; Drug: cetuximab; Drug: Docetaxel Sponsors: M.D. Anderson Cancer Center; Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Docetaxel | Erbitux | Research | Skin Cancer | Squamous Cell Carcinoma | Taxotere